| Oscar Insurance Guidelines | Services | 2025-11-01 |
| Oscar Insurance Guidelines | Oscar Clinical Guideline: Experimental or Investigational Services, Products, Drugs, and Biologicals | 2025-11-01 |
| Oscar Insurance Guidelines | Luxturna (voretigene neparvovec-rzyl) | 2025-11-01 |
| Oscar Insurance Guidelines | Spevigo (spesolimab-sbzo) | 2025-11-01 |
| Oscar Insurance Guidelines | Zynteglo (betibeglogene autotemcel) | 2025-11-01 |
| Oscar Insurance Guidelines | Preferred Physician-Administered Specialty Drugs | 2025-11-01 |
| Oscar Insurance Guidelines | Allergy (Allergen) Immunotherapy | 2025-11-01 |
| Oscar Insurance Guidelines | limited to the Commercial Preferred Physician-Administered Specialty Drugs | 2025-11-01 |
| UHC UMR Medical and Drug | Alpha1-Proteinase Inhibitors – Commercial Medical Benefit Drug Policy | 2025-11-01 |
| UHC UMR Medical and Drug | Brineura® (Cerliponase Alfa) – Commercial Medical Benefit Drug Policy | 2025-11-01 |